Detailansicht

Wissensnetz

Person

Michael Sticherling

Arzt

Name	Michael Sticherling
Ort	Deutschland
Beruf	Arzt (charakteristischer Beruf)
Datensatztyp	Person
GND-Nummer	1048396029
Datensatz-ID	1048396029
Beteiligt an alle anzeigen Guselkumab demonstrates long-term efficacy and maintenance of treatment response post-withdrawal in systemic-treatment naïve patients and non-responders to fumaric acid esters: Results from parts II and III of a randomised, active-comparator-controlled phase IIIb trial (POLARIS) Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials Chronische Entzündungserkrankungen in Deutschland : Eine Querschnittanalyse über Begleiterkrankungen und Arzneimitteleinsatz Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid S2k‐Leitlinie zur Diagnostik und Therapie des Schleimhautpemphigoids Beyond-Mild Psoriasis: A Consensus Statement on Calcipotriol and Betamethasone Dipropionate Foam for the Topical Treatment of Adult Patients Behandlung der Psoriasis mit Secukinumab : Praxisrelevante Hinweise Genetic analysis of MPO variants in four psoriasis subtypes in patients from Germany S2k guideline: Diagnosis and management of cutaneous lupus erythematosus - Part 1: Classification, diagnosis, prevention, activity scores S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics COVID‐19 and implications for dermatological and allergological diseases COVID‐19 and implications for dermatological and allergological diseases Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS) S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update Die Bedeutung von IL-8 bei der kutanen Entzündung

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Michael Sticherling

Guselkumab demonstrates long-term efficacy and maintenance of treatment response post-withdrawal in systemic-treatment naïve patients and non-responders to fumaric acid esters: Results from parts II and III of a randomised, active-comparator-controlled phase IIIb trial (POLARIS)

Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials

Chronische Entzündungserkrankungen in Deutschland : Eine Querschnittanalyse über Begleiterkrankungen und Arzneimitteleinsatz

Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry

S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid

S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid

S2k‐Leitlinie zur Diagnostik und Therapie des Schleimhautpemphigoids

Beyond-Mild Psoriasis: A Consensus Statement on Calcipotriol and Betamethasone Dipropionate Foam for the Topical Treatment of Adult Patients

Behandlung der Psoriasis mit Secukinumab : Praxisrelevante Hinweise

Genetic analysis of MPO variants in four psoriasis subtypes in patients from Germany

S2k guideline: Diagnosis and management of cutaneous lupus erythematosus - Part 1: Classification, diagnosis, prevention, activity scores

S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics

S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics

COVID‐19 and implications for dermatological and allergological diseases

COVID‐19 and implications for dermatological and allergological diseases

Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS)

S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update

S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update

Die Bedeutung von IL-8 bei der kutanen Entzündung